. Author manuscript; available in PMC: 2020 May 22.

Published in final edited form as: Clin J Oncol Nurs. 2010 Aug;14(4):419–422. doi: 10.1188/10.CJON.419-422

Table 3.

Smoldering Multiple Myeloma to Multiple Myeloma: Predictors of Progression at Five Years

RISK FACTOR	MAYO CLINIC (%)^a	PETHEMA (%)^b
0	-	4
1	25	46
2	51	72
3	76	-

Risk factors were bone marrow plasma cells of 10% or higher, monoclonal protein 3 g/dl or higher, and serum-free light chain ratio lower than 0.125 or higher than 8.

Risk factors were 95% or higher abnormal plasma cells by flow cytometry and reduction of uninvolved immunoglobulins.

PETHEMA—Programa Para el Estudio de la Terapéutica en Hemopatía Maligna (Program for the Study of Therapy in Hematologic Malignancies)

Note. Based on information from Dispenzieri et al., 2008;Perez-Persona et al., 2007.